Skip to main content

Table 2 Binary logistic regression analysis for sorafenib response

From: Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study

Variable

 

Univariate analysis

Multivariate analysis

 

OR (95% CI)

P

OR (95% CI)

P

Age (year)

 

0.994 (0.963–1.027)

0.719

  

Sex

(Female)

0.570 (0.203–1.603)

0.287

  

Body mass index (kg/m2)

 

0.885 (0.783–1.000)

0.050

  

ECOG PS

(1 vs. 0)

3.000 (0.627–14.358)

0.169

  

Etiology

HCV vs. nonviral

0.440 (0.167–1.16)

0.097

0.612 (0.179–2.088)

0.433

 

HBV vs. nonviral

0.200 (0.055–0.722)

0.014

0.133 (0.027–0.666)

0.014

Ascites

2 vs. 1

2.333 (0.473–11.506)

0.298

  

Platelet (×103/μL)

 

1.006 (1.001–1.011)

0.017

1.005 (0.999–1.011)

0.103

Creatinine (mg/dL)

 

1.115 (0.529–2.348)

0.775

  

Albumin (g/dL)

 

1.168 (0.488–2.794)

0.727

  

Total bilirubin (mg/dL)

 

1.541 (0.698–3.405)

0.285

  

Prothrombin time (INR)

 

6.922 (0.164–291.871)

0.311

  

MELD

 

1.208 (0.937–1.558)

0.145

  

Macrovascular invasion

 

1.615 (0.71–3.677)

0.253

  

Extrahepatic spread

 

1.506 (0.708–3.205)

0.288

  

BCLC stage

B vs. A

1.000 (0.315–3.174)

1.000

0.808 (0.203–3.224)

0.763

 

C vs. A

2.895 (1.002–8.364)

0.050

3.476 (0.987–12.243)

0.052

Log AFP (ng/dL)

 

1.013 (0.779–1.317)

0.925

  

Log PIVKA-II (mAU/mL)

 

1.989 (1.359–2.911)

< 0.001

1.724 (1.124–2.644)

0.013

Log Angiopoietin 2 (ng/mL)

 

3.754 (0.534–26.374)

0.183

  

Log CD117 (ng/mL)

 

2.895 (0.612–13.687)

0.18

  

bFGF (pg/mL)

 

1.321 (1.092–1.598)

0.004

1.326 (1.077–1.634)

0.008

Log HGF (pg/mL)

 

16.534 (1.275–214.349)

0.032

23.438 (0.750–732.109)

0.072

LOXL2 (ng/mL)

 

0.769 (0.533–1.11)

0.160

  

Log sVEGFR1 (ng/mL)

 

0.272 (0.047–1.592)

0.149

  

AAR

 

1.373 (0.84–2.246)

0.206

  

APRI

 

0.971 (0.718–1.314)

0.85

  

FIB4

 

0.926 (0.842–1.02)

0.12

  

Lok index

 

0.722 (0.154–3.386)

0.68

  

P2/MS

 

1.004 (0.998–1.01)

0.179

  
  1. Abbreviations: OR odds ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, MELD model for end-stage liver disease, INR international normalized ratio, AFP alpha-fetoprotein, PIVKA-II protein induced by vitamin K absence-II, Ang2 angiopoietin-2, bFGF basic fibroblast growth factor, HGF hepatocyte growth factor, LOXL2 lysyl oxidase-like 2, PDGFRb platelet-derived growth factor receptor β, sVEGFR1 soluble vascular endothelial growth factor receptor-1, AAR aspartate aminotransferase/alanine aminotransferase ratio, APRI aspartate aminotransferase to platelet ratio index, FIB-4 fibrosis 4
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us